Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 76.07

+0.9%

Nov 12 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1469)	12/23/2005 3:12:46 PM
From: Jibacoa	Read Replies (2) of 3722

EXAS Is having a good upmove today. Apparently after a comment from Tin Beyers at the Motley Fool pointing out that EXAS has a gross margin of 95.4% and mentioning that its DNA-based test, PreGen-Plus, screens for colorectal Ca., and LH has a deal with it to help bringing the tests to patients. He also pointed out that EXAS' enterprise value is around $13M, with most of it in cash. He estimated that the ongoing operations are trading for just 25% of the market cap. He mentioned that EXAS is dependent on LH as its distribution partner and that PreGen-Plus is still having to earn converts among physicians, which he considers big risks, but he thinks that Exact "is cheap right now". EXAS reportedly has around $1.40 in cash/shr and no significant LTD. The insiders hold more than 15% of the stock. The stock traded at 10.30AM at the Sept.23 H of 2.40 Intraday support is now at 2.18 and resistance at 2.28 The stock is still up more than 11% and volume is over 530Ks bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next